CN117126153A - New coronavirus inhibitor, preparation method, pharmaceutical composition and application thereof - Google Patents
New coronavirus inhibitor, preparation method, pharmaceutical composition and application thereof Download PDFInfo
- Publication number
- CN117126153A CN117126153A CN202210545003.8A CN202210545003A CN117126153A CN 117126153 A CN117126153 A CN 117126153A CN 202210545003 A CN202210545003 A CN 202210545003A CN 117126153 A CN117126153 A CN 117126153A
- Authority
- CN
- China
- Prior art keywords
- hydrogen
- pharmaceutically acceptable
- added
- independently selected
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 17
- -1 preparation method Substances 0.000 title claims description 44
- 238000002360 preparation method Methods 0.000 title abstract description 11
- 241000711573 Coronaviridae Species 0.000 title description 17
- 239000003112 inhibitor Substances 0.000 title description 2
- 239000003814 drug Substances 0.000 claims abstract description 13
- 238000011282 treatment Methods 0.000 claims abstract description 9
- 208000001528 Coronaviridae Infections Diseases 0.000 claims abstract description 7
- 238000011321 prophylaxis Methods 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 59
- 125000000217 alkyl group Chemical group 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims description 21
- 239000001257 hydrogen Substances 0.000 claims description 21
- 125000003545 alkoxy group Chemical group 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 17
- 150000002367 halogens Chemical class 0.000 claims description 17
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 14
- 125000001424 substituent group Chemical group 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 9
- 208000025721 COVID-19 Diseases 0.000 claims 1
- 208000019202 Orthocoronavirinae infectious disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 108700003471 Coronavirus 3C Proteases Proteins 0.000 abstract description 3
- 108700002673 Coronavirus M Proteins Proteins 0.000 abstract description 3
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 abstract description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 90
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 63
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 60
- 239000000243 solution Substances 0.000 description 41
- 238000005481 NMR spectroscopy Methods 0.000 description 35
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 23
- 238000005406 washing Methods 0.000 description 22
- 239000000203 mixture Substances 0.000 description 19
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 18
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 18
- 239000007787 solid Substances 0.000 description 17
- 239000007788 liquid Substances 0.000 description 15
- JKQOCRHWVAAVFB-UHFFFAOYSA-N 4-methyl-3-n-(4-pyridin-3-yl-1,3-thiazol-2-yl)benzene-1,3-diamine Chemical compound CC1=CC=C(N)C=C1NC1=NC(C=2C=NC=CC=2)=CS1 JKQOCRHWVAAVFB-UHFFFAOYSA-N 0.000 description 13
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 238000002390 rotary evaporation Methods 0.000 description 11
- 239000010410 layer Substances 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 229910052786 argon Inorganic materials 0.000 description 9
- 150000002431 hydrogen Chemical class 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 239000003826 tablet Substances 0.000 description 7
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 5
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 5
- 239000006184 cosolvent Substances 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- 239000005711 Benzoic acid Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 235000010233 benzoic acid Nutrition 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 125000001589 carboacyl group Chemical group 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- GXSBBIVHFLDEDZ-UHFFFAOYSA-N n-(2-methyl-5-nitrophenyl)-4-pyridin-3-yl-1,3-thiazol-2-amine;hydrobromide Chemical compound Br.CC1=CC=C([N+]([O-])=O)C=C1NC1=NC(C=2C=NC=CC=2)=CS1 GXSBBIVHFLDEDZ-UHFFFAOYSA-N 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 241000315672 SARS coronavirus Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- WEGYGNROSJDEIW-UHFFFAOYSA-N 3-Acetylpyridine Chemical compound CC(=O)C1=CC=CN=C1 WEGYGNROSJDEIW-UHFFFAOYSA-N 0.000 description 2
- ZPTVNYMJQHSSEA-UHFFFAOYSA-N 4-nitrotoluene Chemical compound CC1=CC=C([N+]([O-])=O)C=C1 ZPTVNYMJQHSSEA-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 241001678559 COVID-19 virus Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 101800004803 Papain-like protease Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000002662 enteric coated tablet Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000008299 semisolid dosage form Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- HNVIQLPOGUDBSU-OLQVQODUSA-N (2s,6r)-2,6-dimethylmorpholine Chemical compound C[C@H]1CNC[C@@H](C)O1 HNVIQLPOGUDBSU-OLQVQODUSA-N 0.000 description 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004750 (C1-C6) alkylaminosulfonyl group Chemical group 0.000 description 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 1
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 description 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 1
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- UCRIXEWTILHNCG-UHFFFAOYSA-N 1-ethyl-2h-pyridine Chemical compound CCN1CC=CC=C1 UCRIXEWTILHNCG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 101800001779 2'-O-methyltransferase Proteins 0.000 description 1
- 101800003073 2'-O-methyltransferase nsp16 Proteins 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- CQGPVWQMYRIQRG-UHFFFAOYSA-N 2-methyl-4-(1-methylpiperazin-2-yl)benzoic acid Chemical compound CN1CCNCC1C1=CC=C(C(O)=O)C(C)=C1 CQGPVWQMYRIQRG-UHFFFAOYSA-N 0.000 description 1
- XUBUJTVBAXQIKG-UHFFFAOYSA-N 2-morpholin-4-ylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1N1CCOCC1 XUBUJTVBAXQIKG-UHFFFAOYSA-N 0.000 description 1
- MLKYVKMIBGUNOC-UHFFFAOYSA-N 3,7-dimethylpurine-2,6-dione;7h-purine Chemical compound C1=NC=C2NC=NC2=N1.CN1C(=O)NC(=O)C2=C1N=CN2C MLKYVKMIBGUNOC-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QYBXZYYECZFQRX-UHFFFAOYSA-N 4-(morpholin-4-ylmethyl)benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CN1CCOCC1 QYBXZYYECZFQRX-UHFFFAOYSA-N 0.000 description 1
- DJAAOYBMOGDECA-UHFFFAOYSA-N 4-morpholin-4-ylpyridine-3-carboxylic acid Chemical compound OC(=O)C1=CN=CC=C1N1CCOCC1 DJAAOYBMOGDECA-UHFFFAOYSA-N 0.000 description 1
- KMQLIDDEQAJAGJ-UHFFFAOYSA-N 4-oxo-4-phenylbutyric acid Chemical compound OC(=O)CCC(=O)C1=CC=CC=C1 KMQLIDDEQAJAGJ-UHFFFAOYSA-N 0.000 description 1
- KDVYCTOWXSLNNI-UHFFFAOYSA-N 4-t-Butylbenzoic acid Chemical compound CC(C)(C)C1=CC=C(C(O)=O)C=C1 KDVYCTOWXSLNNI-UHFFFAOYSA-N 0.000 description 1
- CSJQLIMNCLFPLZ-UHFFFAOYSA-N 4-tert-butyl-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1C(C)(C)C CSJQLIMNCLFPLZ-UHFFFAOYSA-N 0.000 description 1
- DSBIJCMXAIKKKI-UHFFFAOYSA-N 5-nitro-o-toluidine Chemical compound CC1=CC=C([N+]([O-])=O)C=C1N DSBIJCMXAIKKKI-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 101000666833 Autographa californica nuclear polyhedrosis virus Uncharacterized 20.8 kDa protein in FGF-VUBI intergenic region Proteins 0.000 description 1
- 101000977027 Azospirillum brasilense Uncharacterized protein in nodG 5'region Proteins 0.000 description 1
- 101000962005 Bacillus thuringiensis Uncharacterized 23.6 kDa protein Proteins 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101000785191 Drosophila melanogaster Uncharacterized 50 kDa protein in type I retrotransposable element R1DM Proteins 0.000 description 1
- 101000747704 Enterobacteria phage N4 Uncharacterized protein Gp1 Proteins 0.000 description 1
- 101000861206 Enterococcus faecalis (strain ATCC 700802 / V583) Uncharacterized protein EF_A0048 Proteins 0.000 description 1
- 101000769180 Escherichia coli Uncharacterized 11.1 kDa protein Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000711467 Human coronavirus 229E Species 0.000 description 1
- 241001109669 Human coronavirus HKU1 Species 0.000 description 1
- 241000482741 Human coronavirus NL63 Species 0.000 description 1
- 241001428935 Human coronavirus OC43 Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101000976301 Leptospira interrogans Uncharacterized 35 kDa protein in sph 3'region Proteins 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 101000658690 Neisseria meningitidis serogroup B Transposase for insertion sequence element IS1106 Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 101800000514 Non-structural protein 4 Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101000748660 Pseudomonas savastanoi Uncharacterized 21 kDa protein in iaaL 5'region Proteins 0.000 description 1
- 101800001255 Putative 2'-O-methyl transferase Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 101710153041 Replicase polyprotein 1a Proteins 0.000 description 1
- 101710151619 Replicase polyprotein 1ab Proteins 0.000 description 1
- 101000584469 Rice tungro bacilliform virus (isolate Philippines) Protein P1 Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 101000818096 Spirochaeta aurantia Uncharacterized 15.5 kDa protein in trpE 3'region Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 101000766081 Streptomyces ambofaciens Uncharacterized HTH-type transcriptional regulator in unstable DNA locus Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101000804403 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized HIT-like protein Synpcc7942_1390 Proteins 0.000 description 1
- 101000750910 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized HTH-type transcriptional regulator Synpcc7942_2319 Proteins 0.000 description 1
- 101000644897 Synechococcus sp. (strain ATCC 27264 / PCC 7002 / PR-6) Uncharacterized protein SYNPCC7002_B0001 Proteins 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 101000916336 Xenopus laevis Transposon TX1 uncharacterized 82 kDa protein Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 101001000760 Zea mays Putative Pol polyprotein from transposon element Bs1 Proteins 0.000 description 1
- 101000678262 Zymomonas mobilis subsp. mobilis (strain ATCC 10988 / DSM 424 / LMG 404 / NCIMB 8938 / NRRL B-806 / ZM1) 65 kDa protein Proteins 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000005257 alkyl acyl group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- YOAODOSOQLDRID-UHFFFAOYSA-J dicalcium;hydrogen phosphate;sulfate Chemical compound [Ca+2].[Ca+2].OP([O-])([O-])=O.[O-]S([O-])(=O)=O YOAODOSOQLDRID-UHFFFAOYSA-J 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- JYVHOGDBFNJNMR-UHFFFAOYSA-N hexane;hydrate Chemical compound O.CCCCCC JYVHOGDBFNJNMR-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- QZJMONDPQWPMGI-UHFFFAOYSA-N lithium;azane Chemical compound [Li+].N QZJMONDPQWPMGI-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- ODLHGICHYURWBS-FOSILIAISA-N molport-023-220-444 Chemical compound CC(O)COC[C@@H]([C@@H]([C@H]([C@@H]1O)O)O[C@@H]2O[C@H]([C@H](O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O3)[C@@H](O)[C@@H]2O)COCC(O)C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@H]3O[C@H]1COCC(C)O ODLHGICHYURWBS-FOSILIAISA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- JQRYUMGHOUYJFW-UHFFFAOYSA-N pyridine;trihydrobromide Chemical compound [Br-].[Br-].[Br-].C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1 JQRYUMGHOUYJFW-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical group [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The application belongs to the technical field of medicines and mainly relates to coronavirus M pro Protease inhibitors, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments, in particular for the treatment or prophylaxis of coronavirus infections.
Description
Technical Field
The application belongs to the technical field of medicines and mainly relates to coronavirus M pro Protease inhibitors, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments, in particular for the treatment or prophylaxis of coronavirus infections.
Background
Based on the high prevalence, broad distribution and rapid variability of coronaviruses. Vaccines have certain limitations in front of evolving coronaviruses, and therefore, there is an urgent need to develop highly specific and potent drugs against coronavirus targets, which are of great importance for the treatment and prevention of coronavirus epidemics and recurrence.
Coronaviruses are subfamilies of the orthocoronaviridae that belong to the order of the order coronaviridae. The coronavirus genome comprises 6-12 Open Reading Frames (ORFs), the first of which (ORF 1 a/b) is used to directly translate two polyproteins pp1a and pp1ab, which are cleaved by 3CL protease (M pro ) Functionalized into 16 nonstructural proteins (nsps). The protease is also called M pro Or papain-like protease (PLP). These functional nsp4 to nsp16 are linked by M pro Cleavage releases important roles responsible for replication and transcription of the viral genome, and other roles such as protein translation, cleavage, modification, and nucleic acid synthesis. Thus, M is suppressed pro Can effectively block viral RNA replication and transcription, and further block viral proliferation.
And the comparison of gene sequences shows that M pro of three coronaviruses of SARS-CoV-2, SARS-CoV and MERS-CoV show high structural similarity and conservation. The amino acid sequence of M pro of the three shows that the similarity can be up to 96.1%. M without homology in human pro Proteases, which make M pro The protease becomes an ideal specific antiviral target spot and can be used for developing anti-coronavirus medicaments capable of inhibiting proliferation of various coronaviruses.
However, no available M has been reported so far pro The aim of the present inventors was therefore to propose coronavirus M with good activity pro Protease inhibitors and are useful in the treatment or prevention of coronavirus infections.
Disclosure of Invention
The object of the present application is to develop a medicament for the treatment or prevention of novel coronavirus infections.
The present inventors have found, through intensive studies, that N1- ((pyridinyl-3-) thiazol-4) -phenylenediamine derivatives of the following general formula I have inhibitory activity against new coronaviruses and are less toxic and thus can be used as a medicament for treating or preventing coronavirus infection.
To this end, a first aspect of the application relates to compounds of the general formula I and stereoisomers thereof, and pharmaceutically acceptable salts thereof
1. A compound represented by the general formula (I) and stereoisomers thereof or pharmaceutically acceptable salts thereof,
R 1 independently selected from hydrogen, halogen or C 1-10 Straight-chain or branched alkyl, trifluoromethyl or C 1-10 Linear or branched alkoxy groups;
R 2 independently selected from hydrogen, halogen or C 1-10 Straight-chain or branched alkyl, trifluoromethyl or C 1-10 Linear or branched alkoxy groups;
R 3 independently selected from hydrogen, halogen or C 1-10 Straight-chain or branched alkyl, trifluoromethyl or C 1-10 Straight or branched chain alkoxy groups.
R 4 Independently selected from hydrogen, halogen or C 1-10 Straight-chain or branched alkyl, trifluoromethyl or C 1-10 Linear or branched alkoxy groups;
R 5 independently selected from
a) Substituted or unsubstituted C 1-10 A linear or branched alkyl group, said substituent being selected from I, cl, br or F;
b)-CO-R 6 a group, wherein R is 6 Independently selected from H or phenyl optionally substituted with at least one heteroatom, six membered heteroaryl, or phenyl substituted with at least one five or six membered heterocyclyl, six membered heteroaryl.
2. A compound according to claim 1, wherein the compound is preferably,
when R is 1 Is methyl, R 2 、R 3 、R 4 Is hydrogen, R 5 Among the specific compounds having the meaning described in b) above,
R 6 the radicals being selected from
(i) Phenyl or substituted variants thereof, bearing any combination of one or more substituents at any one ring position, e.g. halogen, C 1-10 Alkyl, trifluoromethyl and C 1-10 An alkoxy group;
(ii)R 7 、R 8 substituted aminomethylphenyl wherein R is 7 、R 8 Selected from aryl groups, e.g. phenyl groups, or substituted variants thereof, bearing any combination of one or more substituents, e.g. halogen, C, at any ring position 1-10 Alkyl, trifluoromethyl and C 1-10 An alkoxy group; heteroaryl, e.g. 2, 3 or 4-pyridyl, which may additionally bear any combination of one or more substituents, e.g. halogen, C 1-10 Alkyl, trifluoromethyl and C 1-10 An alkoxy group.
3. A compound according to claim 2, and stereoisomers thereof, and pharmaceutically acceptable salts thereof, more preferably,
when R is 1 Is methyl, R 2 、R 3 、R 4 Is hydrogen, R 5 In the particular compounds having the meaning described in b) above, R 6 Independently selected from hydrogen, 4-tert-butylphenyl, 4-tert-butyl-3-methoxyphenyl, 2-morpholinophenyl, 2-morpholino-4-pyridinyl;
when R is 1 Is methyl, R 2 、R 3 、R 4 Is hydrogen, R 5 In the particular compounds having the meaning described in b) above, R 6 In particular compounds whose radicals have the meanings described in (iii) above,
R 7 、R 8 independently selected from hydrogen, 3, 5-dimethylmorpholinyl, 4- (furan-2-carbonyl) piperazin-1-yl, 4-methanesulfonyl) piperazinyl, 4-formylpiperazinyl, 4-phenylbutyryl, morpholinyl;
4. a compound according to claim 3, most preferably,
a further aspect of the application relates to a pharmaceutical composition comprising a therapeutically and/or prophylactically effective amount of a compound according to any one of the first aspect of the application and stereoisomers thereof, pharmaceutically acceptable salts thereof, and optionally one or more pharmaceutically acceptable carriers or excipients.
The application also provides the use of a compound according to any one of the first aspect of the application, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to any one of the eighth aspect of the application, in the manufacture of a medicament for the treatment or prophylaxis of a coronavirus infection. Among them, coronaviruses include HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, severe acute respiratory syndrome coronavirus (SARS-CoV) and middle east respiratory virus coronavirus (MERS) novel coronavirus SARS-CoV-2.
Summary of The Invention
Various aspects and features of the application are described further below.
All documents cited herein are incorporated by reference in their entirety and are incorporated by reference herein to the extent they are not inconsistent with this application. Furthermore, various terms and phrases used herein have a common meaning known to those skilled in the art, and even though they are still intended to be described and explained in greater detail herein, the terms and phrases used herein should not be construed to be inconsistent with the ordinary meaning in the sense of the present application. The following are definitions of various terms used in the present application, which are applicable to terms used throughout the specification of the present application unless otherwise specified in the specific context.
As used herein, the term "alkyl" refers to an alkyl group having the indicated number of carbon atoms, which is a straight or branched chain alkyl group, and which may include its sub-groups, e.g., where "C" is mentioned 1-10 Alkyl "when it is alsoMay include C 1-10 Alkyl, C 2-8 Alkyl, C 1-7 Alkyl groups and the like, and specific groups such as n-hexyl, n-heptyl, octyl, decyl, and the like.
The term "stereoisomer" is well known in the art in reference to a given compound and refers to another compound having the same formula, wherein the atoms constituting the other compound are spatially oriented in a different manner, but wherein the atoms of the other compound are identical to the atoms of the given compound in atomic and other atomic junctions (e.g., enantiomers, diastereomers and geometric isomers), see, e.g., morrison and Boyde Organic Chemistry,1983, 4 th edition, allnnandBacon. Boston, mass, p.123.
The application is described as "C 1-10 Alkyl "is a straight or branched chain alkyl of 1 to 10 carbon atoms and includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, sec-butyl, pentyl, neopentyl, hexyl and the like.
"C" as described in the present application 1-10 Alkoxy "is a straight or branched chain alkoxy of 1 to 10 carbon atoms and includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, pentoxy, hexoxy and the like.
"halogen" as used herein includes fluorine, chlorine, bromine, iodine atoms.
Said aryl, aryl C 1-6 Alkyl, C 3-8 Cycloalkyl, heteromonocyclic group C 1-6 Alkyl, bridged ring radicals or R 9 And R is 10 The amino atom to which it is attached forming a heteromonocyclic group may be further substituted by a substituent selected from the group consisting of hydroxy, amino, carboxyl, halogen, mercapto, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkanoyl, di (C) 1-6 Alkyl) amino, C 1-6 Alkylamino group C 1-6 Alkyl, C 1-6 Alkylcarbonyl, C 1-6 Alkylcarbonyloxy, C 1-6 Alkoxycarbonyl group, C 1-6 Alkylsulfonylamino, aminosulfonyl, C 1-6 Alkylaminosulfonyl, di (C) 1-6 Alkyl) sulfamoyl, sulfamoyl C 1-6 Alkyl, C 1-6 Alkylamido C 1-6 Alkylamino group C 1-6 Alkanoyl, di (C) 1-6 Alkyl) amino C 1-6 Alkanoyl, amino C 1-6 Alkanoyl, amino C 1-6 Alkylacyl C 1-6 Alkyl or C substituted by hydroxy, amino, halogen 1-6 Alkyl or C 1-6 An alkoxy group.
With respect to any of the above groups containing one or more substituents, it will of course be appreciated that such groups do not include any substitution or substitution patterns that are stereoisomers and/or that are not synthetically feasible. Furthermore, the compounds of the present application include all stereochemical isomers resulting from the substitution of these compounds.
"optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not. For example, "optionally substituted" means that one group may or may not be substituted with the described substituent.
Pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. Salts from inorganic bases include, but are not limited to: sodium, potassium, ammonium lithium, calcium and magnesium salts. Salts from organic bases include, but are not limited to; primary, secondary and tertiary amines, substituted amines (including naturally substituted amines), and salts of cyclic amines, including: isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, tromethamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine ethylenediamine, glucosamine, N-alkyl glucosamine, theobromine purine, piperazine, piperidine and N-ethyl pyridine. It will also be appreciated that other carboxylic acid derivatives will use the practice of the present application, for example, carboxylic acid amides, including formamide, lower alkyl formamide, di (lower alkyl) formamide, and the like.
Pharmaceutically acceptable acid addition salts can be prepared from inorganic and organic acids. Salts from mineral acids include: nicotinic acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Salts from organic acids include: acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.
The compounds of the application generally comprise one or more chiral centers. The present application is therefore intended to include racemic compounds, diastereomers, enantiomers and mixtures enriched in one or more stereoisomers. The scope of the application as described and claimed includes the racemic forms of the compounds as well as the individual enantiomers and non-racemic compounds thereof.
As used herein, the term "effective amount" refers to the amount of a drug that achieves treatment and/or prevention of a disease or disorder described herein in a subject.
The term "pharmaceutical composition" as described herein, which may also refer to "composition", may be used to effect treatment and/or prophylaxis of a disease or condition described herein in a subject, particularly a mammal.
As used herein, the term "subject" may refer to a patient or other animal, particularly a mammal, such as a human, dog, monkey, cow, horse, etc., who receives a compound of formula I of the application or a pharmaceutical composition thereof to treat and/or prevent a disease or condition described herein.
As used herein, the term "disease and/or disorder" refers to a physical state of the subject that is associated with the disease and/or disorder of the present application. For example, the diseases and/or conditions of the present application may refer to a physical condition, such as a condition that is inflammatory in the lung, or a condition, such as a condition that manifests as pneumonia. The physical and disease states are not distinguished herein, or may be referred to interchangeably, e.g. "pulmonary inflammation" and "pneumonia".
As described herein, "%" refers to weight/weight percent, particularly where solid materials are described, unless otherwise indicated. Of course, in describing a liquid substance, the "%" may refer to a weight/volume percentage (in the case of a solid being dissolved in a liquid) or may refer to a volume/volume percentage (in the case of a liquid being dissolved in a liquid).
The term "pharmaceutically acceptable" as used herein, for example when describing a "pharmaceutically acceptable salt", means that the salt is not only physiologically acceptable to the subject, but may also refer to synthetic materials of pharmaceutical use, such as salts formed as intermediates in the preparation of chiral separations, which, although not directly administered to the subject, may still play a role in obtaining the end products of the present application.
In a further aspect the application also relates to pharmaceutical compositions comprising the compounds of the application as active ingredient. The pharmaceutical compositions may be prepared according to methods well known in the art. Any dosage form suitable for human or animal use may be made by combining the compounds of the application with one or more pharmaceutically acceptable solid or liquid excipients and/or adjuvants. The compounds of the present application are typically present in the pharmaceutical compositions thereof in an amount of 0.1 to 95% by weight.
The compounds of the present application or pharmaceutical compositions containing them may be administered in unit dosage form by the enteral or parenteral route, such as oral, intravenous, intramuscular, subcutaneous, nasal, oral mucosal, ocular, pulmonary and respiratory, cutaneous, vaginal, rectal, etc.
The dosage form may be a liquid, solid or semi-solid dosage form. The liquid dosage forms can be solution (including true solution and colloid solution) emulsion (including o/w type, w/o type and compound emulsion), suspension, injection (including water injection, powder injection and transfusion) eye drops, nasal drops, lotion, liniment and the like, and the solid dosage forms can be tablets (including common tablets, enteric-coated tablets, buccal tablet dispersible tablets, chewable tablets, effervescent tablets and orally disintegrating tablets), capsules (including hard capsules, soft capsules and enteric-coated capsules), granules, powder, pellets, dripping pills, suppositories, films, patches, gas (powder) foggies, sprays and the like; the semisolid dosage form may be an ointment, gel, paste, or the like.
The compound of the application can be prepared into common preparations and also into sustained release preparations, controlled release preparations, targeted preparations and various microparticle administration systems.
For the preparation of the compounds of the present application into tablets, various excipients known in the art may be widely used, including diluents, binders, wetting agents, disintegrants, lubricants, cosolvents. The diluent can be starch, dextrin, sucrose, glucose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, calcium hydrogen phosphate calcium sulfate, calcium carbonate, etc., and the wetting agent can be water, ethanol, isopropanol, etc.; the binder may be starch slurry, dextrin, syrup, honey, dextrose solution, microcrystalline cellulose, acacia slurry, gelatin slurry, sodium carboxymethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, ethyl cellulose, acrylic resin, carbomer, polyvinylpyrrolidone, polyethylene glycol, etc.: the disintegrating agent can be dry starch, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, crospolyvinylpyrrolidone, sodium carboxymethyl cellulose, sodium bicarbonate, citric acid, polyoxyethylene sorbitol fatty acid ester, sodium dodecyl sulfonate, etc., and the lubricant and cosolvent can be pulvis Talci, silicon dioxide, stearic acid, tartaric acid, liquid paraffin, polyethylene glycol, etc.
The tablets may be further formulated into coated tablets, such as sugar coated tablets, film coated tablets, enteric coated tablets, or bilayer and multilayer tablets.
In order to prepare the administration unit into a capsule, the compound of the present application as an active ingredient may be mixed with a diluent and a cosolvent, and the mixture may be directly placed in a hard capsule or a soft capsule. The active ingredient of the compound can be prepared into particles or pellets by mixing with a diluent, an adhesive and a disintegrating agent, and then placed into hard capsules or soft capsules. The various diluents, binder wetting agents, and disintegrants used to prepare tablets of the compounds of the application may also be used dry to prepare capsules of the compounds of the application.
For the preparation of the compound of the present application into injection, water, ethanol, isopropanol, propylene glycol or their mixture may be used as solvent, and appropriate amount of solubilizer, cosolvent, pH regulator and osmotic pressure regulator commonly used in the art may be added. The solubilizer or cosolvent can be poloxamer, lecithin, hydroxypropyl-B-cyclodextrin, etc.; the pH regulator can be phosphate, acetate, hydrochloric acid, sodium hydroxide, etc., and the osmotic pressure regulator can be sodium chloride, mannitol, glucose, phosphate, acetic acid, etc. For example, mannitol, glucose, etc. can be added as propping agent for preparing lyophilized powder for injection.
In addition, colorants, preservatives, fragrances, flavoring agents, or other additives may also be added to the pharmaceutical formulation, if desired.
For the purpose of administration, the drug or the pharmaceutical composition of the present application can be administered by any known administration method to enhance the therapeutic effect.
The dosage of the pharmaceutical composition of the present application may vary widely depending on the nature and severity of the disease to be prevented or treated, the individual condition of the patient or animal, the route of administration and the dosage form, etc. Generally, the compounds of the present application are suitably administered in a daily dosage range of from 0.001 to 150mg/Kg of body weight, preferably from 01 to 100mg/Kg of body weight, more preferably from 1 to 60mg/Kg of body weight and most preferably from 2 to 30mg/Kg of body weight. The above-mentioned dosages may be administered in one dosage unit or in several dosage units, depending on the clinical experience of the physician and the dosage regimen involved in the application of other therapeutic means.
The compounds or compositions of the present application may be administered alone or in combination with other therapeutic or symptomatic agents. When the compound of the present application has a synergistic effect with other therapeutic agents, its dosage should be adjusted according to the actual circumstances.
Detailed Description
The present application will be further described by the following examples, however, the scope of the present application is not limited to the following examples. Those skilled in the art will appreciate that various changes and modifications can be made to the application without departing from the spirit and scope thereof. The present application generally and/or specifically describes the materials used in the test as well as the test methods. Although many materials and methods of operation are known in the art for accomplishing the objectives of the present application, the present application will be described in as much detail herein.
For all of the following examples, standard procedures and purification methods known to those skilled in the art may be used. Unless otherwise indicated, all temperatures are expressed in degrees Celsius. The structure of the compound was determined by nuclear magnetic resonance spectroscopy (NMR) and/or Mass Spectrometry (MS) mp. was the melting point given in degrees celsius, temperature uncorrected.
The structure of the compounds was determined by nuclear magnetic resonance hydrogen spectroscopy (HMR) and Mass Spectrometry (MS). The nuclear magnetic resonance hydrogen spectral shift (8) is given in parts per million (ppm). The nuclear magnetic resonance hydrogen spectrum is measured by a Mercury-600 nuclear magnetic resonance apparatus, tritiated dimethyl sulfoxide (DMS 0-d 6) or deuterated chloroform is used as a solvent, and Tetramethylsilane (TMS) or 3- (trimethylsilyl) sodium deuteropate (TSP) is used as an internal standard.
High resolution mass spectra were determined using an Agilent1100series lc/MSD trap mass spectrometer liquid chromatography-mass spectrometer.
The electronic balance adopts a Yanasome-300 type electronic balance in Japan.
Column chromatography generally uses 200-300 mesh or 300-400 mesh silica gel as a carrier.
The anhydrous solvents were all treated by standard methods. Other reagents were all commercially available in analytical purity.
Preparation example
Synthetic route of preparation example
N- ((2-methyl-5-nitrobenzene) aminothioacyl) acetamide (MT-1)
Ammonium thiocyanate (8.855 g,0.116 mol) was dissolved in 120ml of acetone and heated under stirring in an oil bath at 40 ℃. Acetyl chloride (8.412 ml,0.118 mol) was added dropwise via a constant pressure dropping funnel, as a white solid formed. Stirring for about 30min after the completion of the dropwise addition, and TLC monitoring. Cooled to room temperature, 135ml of acetone solution in which 2-methyl-5-nitroaniline (15.0 g,0.0985 mol) was dissolved was added, and after the addition, stirred at room temperature and monitored by TLC. After the raw materials are reacted completely, 225ml of water is added to precipitate solid, and the solid is filtered by vacuum suction, washed with water and n-hexane to obtain 23.402g of pale yellow solid with the yield of 93.8%. The product is directly put into the next step for use without further purification.
1 H NMR(500MHz,DMSO-d6)δ12.38(s,1H),11.72(s,1H),8.68(s, 1H),8.07(dd,J=8.4,2.4Hz,1H),7.59(d,J=8.4Hz,1H),2.33(s,3H), 2.19(s,3H). 13C NMR(126MHz,DMSO)δ180.3,173.3,145.9,141.8, 138.3,131.9,121.7,121.2,24.3,18.3.
2.2-bromo-1- (pyridine-3) ethanone (MT-Br)
500ml of a single-necked flask was placed in an ice bath, 3-acetylpyridine (5 ml,0.0455 mol) was added, and 33% HBr solution (18.32 ml,0.050 mol) was added. 16.0g of pyridinium tribromide was dispersed in about 200ml of glacial acetic acid, the above solution was added in portions, and after addition, the mixture was stirred at room temperature, a yellow solid precipitated and monitored by TLC. After the raw materials are reacted completely, 500ml of diethyl ether is added and stirred for 10min, and then the mixture is subjected to vacuum filtration, diethyl ether washing and methanol washing to obtain 8.932g of white solid with the yield of 98.1%.
1 H NMR(400MHz,TFA)δ9.69(s,1H),9.30(d,J=8.3Hz,1H), 9.23(s,1H),8.45–8.30(m,1H),4.70(s,2H). 13 C NMR(101MHz, TRIFLUOROACETIC_)δ147.1,144.5,142.7,133.1,128.0,118.5,115.7, 112.9,110.1,27.6.
N- (2-methyl-5-nitrophenyl) -4- (pyridin-3-yl) thiazol-2-amine (MT-2)
N- ((2-methyl-5-nitrobenzene) aminothioacyl) acetamide (MT-1) (3.245 g, 0.0128 mol) was taken in a 250ml bottle and K2CO3 (8.855 g,0.0640 mol) was added and the solution turned yellow and stirred for 10min. 2-bromo-1- (pyridine-3) ethanone (MT-Br) (3.0 g,0.0107 mol) was dispersed in about 10ml methanol and added dropwise to the above solution, followed by stirring at room temperature and TLC monitoring. After the raw materials are reacted completely, about 50ml of water is added into the solution, solids are separated out, and the solution is subjected to vacuum filtration, water washing and diethyl ether washing to obtain 3.12g of yellow solid with the yield of 93.4%. 1 H NMR (500MHz,DMSO-d6)δ9.76(s,1H),9.55(s,1H),9.12(s,1H),8.46(d,J =4.9Hz,1H),8.21(d,J=8.0Hz,1H),7.73(d,J=8.3Hz,1H),7.60(d,J =3.0Hz,1H),7.49–7.26(m,2H),2.37(s,3H). 13 C NMR(126MHz, DMSO)δ164.1,147.4,146.7,146.3,145.8,140.3,134.6,134.5,131.6, 131.0,124.9,116.7,112.9,107.7,19.0.
4.6-methyl-N1- (4- (pyridin-3-yl) thiazol-2-yl) benzene-1, 3-diamine (MT-3)
SnCl2 (1.912 g,10.0 mmol) was added to 15ml of concentrated hydrochloric acid under ice bath. N- (2-methyl-5-nitrophenyl) -4- (pyridin-3-yl) thiazol-2-amine (MT-2) (500 mg,1.60 mmol) was added to the above solution in one portion, and after the addition, the reaction was carried out at room temperature, followed by TLC monitoring. After the raw materials are reacted completely, the mixture is moved to an ice bath for cooling, solid is precipitated, the mixture is filtered under reduced pressure and washed with water, and 899mg of light green solid is obtained, and the yield is 88.6%. 1H NMR(500MHz,DMSO-d6)δ 9.16(s,1H),9.06(d,J=2.2Hz,1H),8.46(dd,J=4.7,1.6Hz,1H),8.18 (dt,J=8.0,1.9Hz,1H),7.39(dd,J=8.0,4.8Hz,1H),7.34(s,1H),7.06 (d,J=2.3Hz,1H),6.84(d,J=8.0Hz,1H),6.27(dd,J=8.1,2.3Hz,1H), 4.91(s,2H),2.08(s,3H). 13 C NMR(101MHz,DMSO)δ167.1,148.7, 147.6,147.5,147.4,140.0,133.3,131.4,130.8,124.1,117.2,110.9,108.4, 104.4,17.5.
6.4- (((3R, 5S) -3, 5-dimethylmorpholino) methyl) benzoic acid (MT-G1)
In a single-necked flask, sodium triacetoxyborohydride (2.933 g,0.014 mol) was added under ice bath, and 30ml of chloroform was added. To the solution was added cis-2, 6-dimethylmorpholine (907 ul, 0.0073 mol) and p-aldehyde benzoic acid (1.0 g,0.0067 mol). After the addition, the mixture was stirred overnight at room temperature and monitored by TLC. After the completion of the reaction, water was added, pH was adjusted to 7 with sodium hydrogencarbonate solution, the aqueous layer was extracted three times with ethyl acetate, pH was then adjusted to acidity, extraction was performed with n-butanol, concentration by rotary evaporation, and filtration to give 750mg of a white solid with a yield of 45.2%. 1 H NMR(500MHz, Methanol-d4)δ8.03(d,J=7.8Hz,2H),7.50(d,J=7.9Hz,2H),3.76 (d,J=8.0Hz,5H),3.00–2.77(m,2H),1.99(t,J=10.9Hz,2H),1.16(d, J=6.4Hz,7H). 13 C NMR(126MHz,Methanol-d4)δ169.3,140.1,131.7, 129.4,71.0,61.7,58.3,17.8.
7.4- (((3R, 5S) -3, 5-Dimethylmorpholino) methyl) -N- (4-methyl-3- ((4- (pyridin-3-yl) thiazol-2-yl) amino) phenyl) benzamide (MT-Z1)
In a two-necked flask, 4- (1-methyl-2-piperazinyl) methylbenzoic acid (200 mg,0.65 mmol) was charged under argon, and 8ml of methylene chloride, triethylamine (194.54 ul,1.40 mmo) was added via syringel) was added with thionyl chloride (70.8 ul,0.976 mmol) and a solid was formed, and the reaction was stirred at room temperature for 1h. Another two-necked flask was charged with 6-methyl-N1- (4- (3-pyridyl) thiazol-2-yl) benzene-1, 3-diamine (73.5 mg,0.26 mmol) dissolved in dichloromethane 8ml and triethylamine (194.54 ul,1.40 mmol) was added. The above solution was slowly added by syringe under ice bath, and after the addition was completed, the solution was stirred at room temperature and monitored by TLC. After the reaction was completed, about 4ml of methanol and 10ml of water were added, and the mixture was stirred for 10 minutes to separate the liquid. The aqueous layer was adjusted to pH 8 with 10% sodium hydroxide solution, about 4ml of methanol, 10ml of methylene chloride was added thereto, and stirred for 10 minutes. Separating, washing an organic layer with water, washing saturated saline, concentrating by rotary evaporation, and separating and purifying by a Flash column to obtain 106mg of a product with the yield of 29.3%. 1 H NMR(500MHz,CDCl3)δ 9.12(s,1H),8.56(d,J=4.5Hz,1H),8.34(s,1H),8.18(d,J=8.1Hz,1H), 8.11(s,1H),7.91(s,1H),7.55(d,J=7.5Hz,2H),7.35(dd,J=8.0,4.8Hz, 2H),7.27–7.19(m,3H),6.93(s,1H),3.87(s,2H),3.69(s,2H),2.82(s, 2H),2.36(s,3H),1.93(s,2H),1.17(d,J=6.3Hz,6H). 13 C NMR(101 MHz,Chloroform-d)δ165.9,165.6,148.7,148.3,147.5,138.9,137.2, 133.4,131.4,130.5,129.6,127.2,124.2,124.2,123.6,115.6,111.5, 103.8,71.5,62.4,59.2,19.1,17.4.
8.4- ((4- (furan-2-carbonyl) piperazin-1-yl) methyl) -N- (4-methyl-3- ((4- (pyridin-3-yl) thiazol-2-yl) amino) phenyl) benzamide (MT-Z3)
In a two-necked flask, 4- ((4- (furan-2-carbonyl) piperazinyl-1) methyl) benzoic acid (278.1 mg,0.88 mmol) was added, argon protected, 8ml dichloromethane, triethylamine (270 ul,1.947 mmol) were added via syringe, and after addition of thionyl chloride (77 ul,1.062 mmol) a solid was formed, and the reaction was stirred at room temperature for 1h. Another two-necked flask was charged with 6-methyl-N1- (4- (3-pyridyl) thiazol-2-yl) benzene-1, 3-diamine (200 mg, 0.706 mmol) dissolved in dichloromethane 8ml and triethylamine (270 ul,1.947 mmol) was added. The above solution was slowly added by syringe under ice bath, and after the addition was completed, the solution was stirred at room temperature and monitored by TLC. After the reaction was completed, about 4ml of methanol and 10ml of water were added, and the mixture was stirred for 3 minutes to separate the liquid. The aqueous layer was adjusted to pH 8 with 10% sodium hydroxide solution, about 4ml of methanol, 10ml of methylene chloride,stirring for 10min. Separating, washing an organic layer with water, washing saturated saline, concentrating by rotary evaporation, and separating and purifying by a Flash column to obtain 88mg of a product with the yield of 21.5%. 1 H NMR(500 MHz,CDCl3)δ9.1(s,1H),8.6(s,1H),8.3(d,J=2.1Hz,1H),8.2(d,J =7.9Hz,1H),8.1(s,1H),7.9(d,J=7.8Hz,2H),7.5(d,J=7.6Hz,3H), 7.4(dd,J=7.9,4.8Hz,1H),7.3–7.2(m,3H),7.0(d,J=3.5Hz,1H),6.9 (s,1H),6.5(dd,J=3.5,1.8Hz,1H),3.9(s,4H),3.7(s,2H),2.6(t,J=5.1 Hz,4H),2.4(s,3H). 13 C NMR(101MHz,Chloroform-d)δ165.9,165.6, 159.1,148.6,148.3,147.8,147.5,143.7,138.9,137.2,134.2,133.5, 131.4,130.5,129.5,127.3,124.3,123.6,116.5,115.7,111.6,111.3, 103.8,62.3,53.1,29.7,17.4.
N- (4-methyl-3- ((4- (pyridin-3-yl) thiazol-2-yl) amino) phenyl) -4- ((4- (methylsulfonyl) piperazin-1-yl) methyl) benzamide (MT-Z5)
In a two-necked flask, 4- ((4- (methylsulfonyl) piperazin-1-yl) methyl) benzoic acid (200 mg,0.67 mmol) was added, protected by argon, 8ml of dichloromethane, triethylamine (121 ul,0.871 mmol) was added via syringe, and after addition of thionyl chloride (53.5 ul,0.737 mmol) a solid was formed and the reaction was stirred at room temperature for 1h. Another two-necked flask was charged with 6-methyl-N1- (4- (3-pyridyl) thiazol-2-yl) benzene-1, 3-diamine (94.6 mg,0.335 mmol) in 8ml of dichloromethane and triethylamine (121 ul,0.871 mmol) was added. The above solution was slowly added by syringe under ice bath, and after the addition was completed, the solution was stirred at room temperature and monitored by TLC. After the reaction was completed, about 4ml of methanol and 10ml of water were added, and the mixture was stirred for 3 minutes to separate the liquid. The aqueous layer was adjusted to pH 8 with 10% sodium hydroxide solution, about 4ml of methanol, 10ml of methylene chloride was added thereto, and stirred for 10 minutes. Separating, washing the organic layer with water, washing with saturated saline, concentrating by rotary evaporation, and separating and purifying by a Flash column to obtain 94mg of product with the yield of 50%. 1 H NMR(500 MHz,Methanol-d4)δ9.11(d,J=2.2Hz,1H),8.50(d,J=2.2Hz,1H), 8.45(dd,J=4.9,1.6Hz,1H),8.37(dt,J=8.0,2.0Hz,1H),7.94(d,J= 7.9Hz,2H),7.52(d,J=8.0Hz,2H),7.49–7.40(m,2H),7.36(dd,J=8.2, 2.2Hz,1H),7.26(s,1H),7.25(d,J=2.3Hz,1H),3.67(s,2H),3.27(t,J= 5.0Hz,5H),2.87(s,3H),2.62–2.58(m,4H),2.36(s,3H). 13 C NMR(101 MHz,Chloroform-d)δ165.8,165.4,148.5,148.3,147.4,138.9,137.1, 134.3,133.5,131.4,130.5,129.8,129.5,127.4,124.1,123.6,115.6, 111.4,103.8,62.0,52.3,45.7,34.4,17.4.
10.4- ((4-formylpiperazin-1-yl) methyl) -N- (4-methyl-3- ((4- (pyridin-3-yl) thiazol-2-yl) amino) phenyl) benzamide (MT-Z6)
In a two-necked flask, 4- ((4-formylpiperazin-1-yl) methyl) benzoic acid (175.8 mg,0.708mmol) was added, and 8ml of methylene chloride, triethylamine (211.6 ul, 1.803 mmol) and thionyl chloride (56.5 ul,0.779 mmol) were added via syringe under argon gas, followed by solid formation and the reaction was stirred at room temperature for 1h. Another two-necked flask was charged with 6-methyl-N1- (4- (3-pyridyl) thiazol-2-yl) benzene-1, 3-diamine (100 mg,0.354 mmol) dissolved in dichloromethane 8ml and triethylamine (211.6 ul, 1.323 mmol) was added. The above solution was slowly added by syringe under ice bath, and after the addition was completed, the solution was stirred at room temperature and monitored by TLC. After the reaction was completed, about 4ml of methanol and 10ml of water were added, and the mixture was stirred for 3 minutes to separate the liquid. The aqueous layer was adjusted to pH 8 with 10% sodium hydroxide solution, about 4ml of methanol, 10ml of methylene chloride was added thereto, and stirred for 10 minutes. Separating, washing an organic layer with water, washing saturated saline, concentrating by rotary evaporation, and separating and purifying by a Flash column to obtain 45mg of a product with the yield of 24.8%. 1 H NMR (500MHz,CDCl3)δ9.1(s,1H),8.6(d,J=4.8Hz,1H),8.4(s,1H),8.2 (d,J=8.1Hz,1H),8.1(s,1H),7.9(d,J=7.1Hz,2H),7.5(d,J=8.0Hz, 2H),7.4(q,J=7.6Hz,2H),7.3–7.2(m,1H),3.5(s,2H),3.2(s,4H),2.5 (d,J=14.3Hz,3H),2.4(s,3H),1.4(t,J=7.4Hz,9H). 13 C NMR(101 MHz,CDCl3)δ165.5,160.8,148.6,148.2,147.4,138.9,137.1,134.1, 133.6,131.4,129.4,129.3,127.3,127.3,124.1,123.6,115.5,111.3,103.8, 62.3,52.3,45.5,17.4.
11.2,2,2-trifluoro-N- (4-methyl-3- ((4- (pyridin-3-yl) thiazol-2-yl) amino) phenyl) acetamide (MT-Z7)
In a two-necked flask, 6-methyl-N1- (4- (3-pyridyl) thiazol-2-yl) benzene-1, 3-diamine (100 mg,0.0035 mmol) was dissolved in methylene chloride (8 ml), triethylamine (73.8 ul, 0.551 mmol) was added, trifluoroacetic anhydride (78.1 mg,0.0037 mmol) was added under ice bath at 0℃in a roomThe reaction was stirred at temperature and monitored by TLC. After the reaction is completed, water is added to adjust the pH to 7-8, dichloromethane extraction, rotary evaporation concentration and Flash column separation and purification are carried out, thus obtaining 97.3mg of product with the yield of 73.1%. 1 H NMR(500MHz,Methanol-d4)δ9.19–9.05(m,1H), 8.55(d,J=4.0Hz,1H),8.52–8.23(m,2H),7.52–7.43(m,1H),7.27(t, J=5.2Hz,3H),3.41–3.34(m,2H),2.40–2.29(m,3H). 13 C NMR(101 MHz,Methanol-d4)δ166.2,155.3,155.0,147.2,147.1,146.3,139.5, 134.84,134.1,131.3,130.6,125.9,123.8,115.7,113.1,104.4,16.4.
N- (4-methyl-3- ((4- (pyridin-3-yl) thiazol-2-yl) amino) phenyl) -4-oxo-4-phenylbutanamide (MT-Z8)
In a two-necked flask, 3-benzoylpropionic acid (200 mg,1.122 mmol) was dissolved in dichloromethane 15ml, EDCI (321.7 mg,1.683 mmol), HOBt (369.2 mg,1.739 mg), triethylamine (280 ul,2.02 mmol) was added under ice-bath, and after disappearance of the starting material, 6-methyl-N1- (4- (3-pyridinyl) thiazol-2-yl) benzene-1, 3-diamine (100 mg,0.354 mmol) was added and monitored by TLC. After the reaction of the raw materials is completed, the raw materials are washed by saturated sodium bicarbonate solution, dried by anhydrous sodium sulfate, filtered and concentrated, and separated and purified by a Flash column to obtain 47mg of a product with the yield of 30.1%. 1 H NMR(500MHz,DMSO-d6)δ10.02(s,1H),9.40(s,1H), 9.15(s,1H),8.48(s,2H),8.36(d,J=7.9Hz,1H),8.03(d,J=7.7Hz,2H), 7.67(t,J=7.2Hz,1H),7.56(t,J=7.6Hz,2H),7.48(s,1H),7.37(d,J= 8.0Hz,1H),7.24–7.09(m,2H),3.37(d,J=5.8Hz,3H),2.76(s,2H), 2.25(s,3H). 13 C NMR(101MHz,DMSO-d6)δ199.4,170.6,166.0, 148.1,147.4,147.0,137.1,134.1,133.6,131.0,131.0,129.2,128.4, 124.3,123.4,114.5,112.1,18.0.
16.4- (tert-butyl) -N- (4-methyl-3- ((4- (pyridin-3-yl) thiazol-2-yl) amino) phenyl) benzamide (MT-0816)
In a two-necked flask, 4-t-butylbenzoic acid (126 mg,0.708 mmol) was added under argon, 8ml of methylene chloride, triethylamine (127.9 ul,0.921 mmol) and thionyl chloride (56.5 ul,0.779 mmol) were added via syringe, and the reaction was stirred at room temperature and monitored by TLC. Another two-necked flask was taken and charged with 6-methyl-N1- (4- (3-pyridyl) thiazol-2-yl) benzene-1, 3-diamine (73.5 mg,0.26 mmo)l) dissolved in dichloromethane 8ml triethylamine (194.54 ul,1.40mmol) was added. The above solution was slowly added by syringe under ice bath, and after the addition was completed, the solution was stirred at room temperature and monitored by TLC. After the reaction was completed, about 4ml of methanol and 10ml of water were added, and the mixture was stirred for 3 minutes to separate the liquid. The aqueous layer was adjusted to pH 8 with 10% sodium hydroxide solution, about 4ml of methanol, 10ml of methylene chloride was added thereto, and stirred for 10 minutes. Separating, washing an organic layer with water, washing saturated saline, concentrating by rotary evaporation, and separating and purifying by a Flash column to obtain 76mg of a product with the yield of 24.2%. 1 H NMR(500MHz,CDCl3)δ9.2(s,1H),8.6 (s,1H),8.5(d,J=7.7Hz,1H),8.5(s,1H),8.1(s,1H),7.9(d,J=8.1Hz, 2H),7.6(s,1H),7.6(d,J=8.1Hz,2H),7.3(d,J=8.0Hz,1H),7.2(d,J= 8.2Hz,1H),7.0(s,1H),2.4(s,3H),1.4(s,10H).
17.4- (tert-butyl) -3-methoxy-N- (4-methyl-3- ((4- (pyridin-3-yl) thiazol-2-yl) amino) phenyl) benzamide (MT-0819)
In a two-necked flask, 3-methoxy-4-tert-butylbenzoic acid (295 mg,1.416 mmol) was added under argon, 8ml of dichloromethane, triethylamine (255.9 ul,1.841 mmol) were added via syringe, and after addition of thionyl chloride (113.0 ul, 1.578 mmol), the reaction was stirred at room temperature and monitored by TLC. Another two-necked flask was charged with 6-methyl-N1- (4- (3-pyridyl) thiazol-2-yl) benzene-1, 3-diamine (200 mg, 0.706 mmol) dissolved in dichloromethane 8ml and triethylamine (255.9 ul,1.841 mmol) was added. The above solution was slowly added by syringe under ice bath, and after the addition was completed, the solution was stirred at room temperature and monitored by TLC. After the reaction was completed, about 4ml of methanol and 10ml of water were added, and the mixture was stirred for 3 minutes to separate the liquid. The aqueous layer was adjusted to pH 8 with 10% sodium hydroxide solution, about 4ml of methanol, 10ml of methylene chloride was added thereto, and stirred for 10 minutes. Separating, washing an organic layer with water, washing saturated saline, concentrating by rotary evaporation, and separating and purifying by a Flash column to obtain 85mg of a product with the yield of 25.4%. 1 H NMR(500MHz,DMSO-d6)1H NMR(500MHz,CDCl3)δ9.13(s,1H),8.58(s,1H),8.35(s,1H),8.26 (d,J=7.9Hz,1H),8.00(s,1H),7.52(d,J=1.7Hz,1H),7.46–7.32(m, 3H),7.25(s,2H),6.96(s,1H),3.95(s,3H),2.37(s,3H),1.43(s,9H). 13 C NMR(101MHz,Chloroform-d)δ166.2,165.7,159.0,147.5,147.4, 146.5,142.7,138.7,137.3,134.4,133.7,131.4,126.7,124.3,118.0, 115.8,111.6,110.8,104.1,55.3,35.2,29.5,17.4.
N- (4-methyl-3- ((4- (pyridin-3-yl) thiazol-2-yl) amino) phenyl) -4- (morpholinomethyl) benzamide (MT-0820)
In a two-necked flask, 4-morpholinomethylbenzoic acid (235 mg,1.062 mmol) was added under argon, 8ml of dichloromethane and triethylamine (127.9ul,0.921 mmol) were added via syringe, and after addition of thionyl chloride (82.2 ul,1.133 mmol), the reaction was stirred at room temperature and monitored by TLC. Another two-necked flask was charged with 6-methyl-N1- (4- (3-pyridyl) thiazol-2-yl) benzene-1, 3-diamine (200 mg, 0.706 mmol) dissolved in dichloromethane 8ml and triethylamine (196.9 ul,1.416 mmol) was added. The above solution was slowly added by syringe under ice bath, and after the addition was completed, the solution was stirred at room temperature and monitored by TLC. After the reaction was completed, about 4ml of methanol and 10ml of water were added, and the mixture was stirred for 3 minutes to separate the liquid. The aqueous layer was adjusted to pH 8 with 10% sodium hydroxide solution, about 4ml of methanol, 10ml of methylene chloride was added thereto, and stirred for 10 minutes. Separating, washing the organic layer with water, washing with saturated saline, concentrating by rotary evaporation, and separating and purifying by a Flash column to obtain 113mg of a product with the yield of 32.9%. 1 H NMR(500MHz,CDCl3)δ9.2– 9.1(m,1H),8.6–8.6(m,1H),8.4(s,1H),8.2(d,J=7.9Hz,1H),8.0(s, 1H),7.9(d,J=7.8Hz,2H),7.6(d,J=7.7Hz,2H),7.4(dd,J=7.9,4.8 Hz,1H),7.3(s,2H),6.9(s,1H),3.8(s,4H),3.7(s,2H),2.6(s,4H),2.4(s, 4H). 13 C NMR(101MHz,Chloroform-d)δ165.8,165.5,148.6,148.3, 147.5,138.9,137.2,133.5,131.4,130.5,129.9,127.3,124.1,123.6, 115.6,111.4,103.8,66.4,62.6,53.4,17.4.
N- (4-methyl-3- ((4- (pyridin-3-yl) thiazol-2-yl) amino) phenyl) -2-morpholinobenzamide (MT-0822)
In a two-necked flask, 2- (4-morpholinyl) benzoic acid (293.5 mg,1.416 mmol) was added, protected by argon, 8ml dichloromethane, triethylamine (255.9ul,1.841 mmol) were added via syringe and after addition of thionyl chloride (113.0 ul, 1.554 mmol) l turned yellow immediately, the reaction was stirred at room temperature and monitored by TLC. Another two-necked flask was taken and charged with 6-methyl-N1- (4- (3-pyridyl) thiazol-2-yl) benzene-1, 3-diamine (200 mg, 0.706 mmol) in dichloromethane 8ml triethylamine (255.9 ul,1.841 mmol) was added. The above solution was slowly added by syringe under ice bath, and after the addition was completed, the solution was stirred at room temperature and monitored by TLC. After the reaction was completed, about 4ml of methanol and 10ml of water were added, and the mixture was stirred for 3 minutes to separate the liquid. The aqueous layer was adjusted to pH 8 with 10% sodium hydroxide solution, about 4ml of methanol, 10ml of methylene chloride was added thereto, and stirred for 10 minutes. Separating, washing an organic layer with water, washing saturated saline, concentrating by rotary evaporation, and separating and purifying by a Flash column to obtain 86mg of a product with the yield of 25.8%. 1 H NMR(500MHz,CDCl3) δ12.1(s,1H),9.1(d,J=2.1Hz,1H),8.6(d,J=4.8Hz,1H),8.5(d,J= 2.1Hz,1H),8.3(dd,J=7.8,1.6Hz,1H),8.3(d,J=7.9Hz,1H),7.5(d,J =7.3Hz,1H),7.5–7.3(m,5H),7.3(d,J=8.1Hz,2H),7.0(s,1H),4.0(t, J=4.5Hz,4H),3.1(t,J=4.5Hz,4H),2.4(s,3H). 13 C NMR(101MHz, Chloroform-d)δ165.8,164.1,150.5,148.2,148.0,147.1,138.9,137.8, 133.9,132.7,132.1,131.5,130.6,127.9,125.6,123.7,123.3,120.5, 115.0,110.6,103.9,67.3,53.7,17.4.
N- (4-methyl-3- ((4- (pyridin-3-yl) thiazol-2-yl) amino) phenyl) -2-morpholinyl nicotinamide (MT-0824)
In a two-necked flask, 4-morpholino nicotinic acid (221.2 mg,1.062 mmol) was added, protected by argon, 8ml of dichloromethane, triethylamine (196.9 ul,1.416 mmol) were added via syringe, and after addition of thionyl chloride (87.35 ul,1.204 mmol), l turned yellow immediately, the reaction was stirred at room temperature and monitored by TLC. Another two-necked flask was charged with 6-methyl-N1- (4- (3-pyridyl) thiazol-2-yl) benzene-1, 3-diamine (200 mg, 0.706 mmol) dissolved in dichloromethane (8 ml), and triethylamine (196.9 ul,1.416mmol) was added. The above solution was slowly added by syringe under ice bath, and after the addition was completed, the solution was stirred at room temperature and monitored by TLC. After the reaction was completed, about 4ml of methanol and 10ml of water were added, and the mixture was stirred for 3 minutes to separate the liquid. The aqueous layer was adjusted to pH 8 with 10% sodium hydroxide solution, about 4ml of methanol, 10ml of methylene chloride was added thereto, and stirred for 10 minutes. Separating, washing the organic layer with water, washing with saturated saline, concentrating by rotary evaporation, and separating and purifying by a Flash column to obtain 104mg of the product with the yield of 31.1%. 1 H NMR(500MHz,CDCl3)δ11.1(s,1H), 9.2(s,1H),8.6(d,J=7.8Hz,1H),8.5(dt,J=10.9,2.8Hz,3H),8.3(d,J =7.9Hz,1H),7.4(q,J=5.2Hz,1H),7.3(dd,J=8.2,2.1Hz,1H),7.3(s, 1H),7.3(d,J=2.0Hz,1H),7.3–7.2(m,1H),7.0(s,1H),3.9(t,J=4.7 Hz,4H),3.3(t,J=4.7Hz,4H),2.4(s,3H). 13 C NMR(101MHz, Chloroform-d)δ165.5,163.2,160.0,152.7,150.4,148.0,147.9,146.9, 140.7,139.0,137.3,134.1,131.5,123.8,123.5,122.0,120.3,114.6, 110.2,104.0,67.1,52.0,17.4.
Examples antiviral Activity experiments
New coronavirus activity inhibition assay
/>
/>
Experimental results
As shown in the table, the compounds MT-Z7 and MT-0820 have certain activity, and MT-Z8 and MT-0819 have better activity on novel coronaviruses, and the IC50 value is 2.294umol/L. The compound MT-Z1 has stronger antiviral activity to the novel coronavirus in experiments, the IC50 value is 0.661umol/L, and the activity is doubled compared with that of the macitenib.
Claims (8)
1. A compound represented by the general formula (I) and stereoisomers thereof or pharmaceutically acceptable salts thereof,
R 1 independently selected from hydrogen, halogen or C 1-10 Straight-chain or branched alkyl, trifluoromethyl or C 1-10 Linear or branched alkoxy groups;
R 2 independently selected from hydrogen, halogen or C 1-10 Straight-chain or branched alkyl, trifluoromethyl or C 1-10 Linear or branched alkoxy groups;
R 3 independently selected from hydrogen, halogen or C 1-10 Straight-chain or branched alkyl, trifluoromethyl or C 1-10 Straight or branched chain alkoxy groups.
R 4 Independently selected from hydrogen, halogen or C 1-10 Straight-chain or branched alkyl, trifluoromethyl or C 1-10 Linear or branched alkoxy groups;
R 5 independently selected from
a) Substituted or unsubstituted C 1-10 A linear or branched alkyl group, said substituent being selected from I, cl, br or F;
b)-CO-R 6 a group, wherein R is 6 Independently selected from H or phenyl optionally substituted with at least one heteroatom, six membered heteroaryl, or phenyl substituted with at least one five or six membered heterocyclyl, six membered heteroaryl.
2. The compound according to claim 1, wherein, when R 1 Is methyl, R 2 、R 3 、R 4 Is hydrogen, R 5 Among the specific compounds having the meaning described in b) above,
R 6 the radicals being selected from
(i) Phenyl or substituted variants thereof, bearing any combination of one or more substituents at any one ring position, e.g. halogen, C 1-10 Alkyl, trifluoromethyl and C 1-10 An alkoxy group;
(ii)R 7 、R 8 substituted aminomethylphenyl wherein R is 7 、R 8 Selected from aryl groups, e.g. phenyl groups, or substituted variants thereof, bearing any combination of one or more substituents, e.g. halogen, C, at any ring position 1-10 Alkyl, trifluoromethyl and C 1-10 An alkoxy group; heteroaryl, e.g. 2, 3 or 4-pyridyl, which may additionally bear any combination of one or more substituents, e.g. halogen, C 1-10 Alkyl, trifluoromethyl and C 1-10 An alkoxy group.
3. A compound according to claim 2, wherein
When R is 1 Is methyl, R 2 、R 3 、R 4 Is hydrogen, R 5 In the particular compounds having the meaning described in b) above, R 6 Independently selected from hydrogen, 4-tert-butylphenyl, 4-tert-butyl-3-methoxyphenyl, 2-morpholinophenyl, 2-morpholino-4-pyridinyl;
when R is 1 Is methyl, R 2 、R 3 、R 4 Is hydrogen, R 5 In the particular compounds having the meaning described in b) above, in the particular compounds having the meaning described in (iii) above for the R6 group,
R 7 、R 8 independently selected from the group consisting of hydrogen, 3, 5-dimethylmorpholinyl, 4- (furan-2-carbonyl) piperazin-1-yl, 4-methanesulfonyl) piperazinyl, 4-formylpiperazinyl, 4-phenylbutyryl, morpholinyl.
4. A compound according to any one of claims 1-3, and stereoisomers thereof, which are chemically acceptable salts, characterized in that said compound is a compound having the structure:
5. a compound according to any one of claims 1 to 4, as well as stereoisomers, chemically acceptable salts thereof, characterized in that the compound is a compound of stereoisomers, pharmaceutically acceptable salts thereof, and optionally one or more pharmaceutically acceptable carriers or excipients.
6. A pharmaceutical composition comprising a compound according to any one of claims 1-4, a pharmaceutically acceptable salt or isomer thereof and other pharmaceutically active ingredients.
7. A pharmaceutical composition comprising a compound according to any one of claims 1 to 4, a pharmaceutically acceptable salt or isomer thereof, together with one or more pharmaceutically acceptable carriers and/or diluents, in any pharmaceutically acceptable dosage form.
8. Use of a compound according to any one of claims 1 to 4, a pharmaceutically acceptable salt or isomer thereof for the manufacture of a medicament for the treatment and/or prophylaxis of novel coronavirus infectious diseases, in particular Covid-19.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210545003.8A CN117126153A (en) | 2022-05-19 | 2022-05-19 | New coronavirus inhibitor, preparation method, pharmaceutical composition and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210545003.8A CN117126153A (en) | 2022-05-19 | 2022-05-19 | New coronavirus inhibitor, preparation method, pharmaceutical composition and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117126153A true CN117126153A (en) | 2023-11-28 |
Family
ID=88860534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210545003.8A Pending CN117126153A (en) | 2022-05-19 | 2022-05-19 | New coronavirus inhibitor, preparation method, pharmaceutical composition and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117126153A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115867278A (en) * | 2020-04-10 | 2023-03-28 | Ab科学有限公司 | Use of masitinib for treating 2019 coronavirus disease (COVID-19) |
-
2022
- 2022-05-19 CN CN202210545003.8A patent/CN117126153A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115867278A (en) * | 2020-04-10 | 2023-03-28 | Ab科学有限公司 | Use of masitinib for treating 2019 coronavirus disease (COVID-19) |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4405602B2 (en) | Histone deacetylase inhibitor | |
JP6283033B2 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
CA2881057C (en) | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b | |
JP2802547B2 (en) | Isoxazoline compounds as anti-inflammatory agents | |
CA3093851A1 (en) | Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same | |
EP3653620B1 (en) | New heteroaryl amide derivatives as selective inhibitors of histone deacetylases 1 and 2 (hdac1-2) | |
JP2006518341A (en) | Hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors | |
JP2001521925A (en) | Therapeutically active compounds based on indazole bioisostere substitution of catechol in PDE4 inhibitors | |
KR101157074B1 (en) | Amide derivatives | |
CN106883279B (en) | A kind of prodrug, preparation method, medical composition and its use | |
CN111410661A (en) | Cap-dependent endonuclease inhibitors and uses thereof | |
CN117126153A (en) | New coronavirus inhibitor, preparation method, pharmaceutical composition and application thereof | |
CN107459511B (en) | Anti-enterovirus 71(EV71) 4-iminooxazolidine-2-ketone compound and preparation method and application thereof | |
AU2024204863A1 (en) | Antiviral 1,3-di-oxo-indene compounds | |
JP2022531251A (en) | Human immunodeficiency virus replication inhibitor | |
ES2863985T3 (en) | New compound, pharmaceutically acceptable salt or optical isomer thereof, method to prepare it and pharmaceutical composition for the prevention or treatment of viral diseases that contain it as an active ingredient | |
CN114075227B (en) | Pyrazole boric acid compound, pharmaceutical composition containing pyrazole boric acid compound and application of pyrazole boric acid compound and pharmaceutical composition | |
EP1844775B1 (en) | Therapeutic agent for the treatment of herpes progenitalis after development of lesions | |
JP2013544855A (en) | Thiazoleamine derivatives and their use as anti-picornavirus infectious agents | |
CN101602750B (en) | Naphthyl, (replacement) aryl, piperazinyl amidine compounds | |
CN112204035A (en) | Substituted 3,4,12,12 a-tetrahydro-1 n1- [1,4] oxazino [3,4-c ] pyrido [2,1-f ] [1,2,4] triazine-6, 8-diones, pharmaceutical compositions, methods of production and uses thereof | |
KR102670554B1 (en) | Novel isoindolinone derivative compounds as caspase inhibitors | |
CN114341137B (en) | Dihydropyrimidine derivatives and uses thereof | |
JP2013505922A (en) | Novel amino acid derivatives, methods for their preparation, and their therapeutic use as inhibitors of carcinogenic signals by the MET family | |
CN107098895B (en) | Benzoylaminothiazolylmethyl quinolinone derivative and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |